Mobilization of peripheral blood stem cells (PBSC) using the @entity1261 ( @entity1261 ) has enabled the collection even from older donors and those with comorbidities. Several clinical parameters have been reported to predict the success of PBSC mobilization. The aim of our study was to evaluate the safety of PBSC donation in a  cohort of 167 sibling donors after mobilization with @entity1261 16  g/kg/day for 5 days during short- and long term follow-up and to analyse the efficacy, @entity137 and factors influencing @entity2280 + mobilization capacity. All 167 sibling donors completed the established mobilization protocol. The median yield was 7.9x106 @entity2280 cells/kg per recipient weight. The optimal target dose of @entity2280 cells >=  4.0x106/kg was achieved in 140 donors (84%). Only in 4 donors (2%) was the @entity2280 + yield < 2x106/kg. No major @entity137 occured.Factors associated with higher PBSC yields included age 51/ L (p 45.5 x  109/L (p = 0.003). Comorbidity score, performance status and donor weight did not significantly influence PBSC yields. Long-term follow-up was possible in 60% (101/167) of the donors. The median length of follow-up from PBSC donation was 11.9 years. Most of these donors reported good or very good general health (91%), and no @entity1583 were observed.The mobilization of PBSC in sibling donors with @entity1261 16  g/kg/day is an effective and safe procedure with no significant short- and long-term @entity137 .

Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with XXXX 16 g/kg/day: efficacy and safety.

@entity2280 :: ('947', 'Gene') :: ['CD34'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor']
@entity1261 :: (1440,Gene) :: ['G-CSF']
